logo
  

Lloyds Banking To Return Surplus Capital To Shareholders In Due Course

Lloyds Banking Group plc (LLOY.L,LYG) said, following a solid start to 2020, the Group is now seeing the emerging economic impact of the coronavirus crisis and this will be reflected in its performance going forward. The Group said it is in a strong financial position and its balance sheet remains well positioned for the current environment.

At the virtual shareholder event, the Chairman, Lord Blackwell, reassured shareholders that the Board remains committed to returning surplus capital to shareholders in due course both through future dividends and potential share buy backs as appropriate.

The Group's Group Executive Committee have asked that they do not receive an annual bonus under the 2020 Group Performance Share Award. The Group Chief Executive and Chief Operating Officer also independently requested not to receive Group Performance Share awards for 2019.

The Group is also introducing a new long-term variable reward, known as the Long Term Share Plan, to replace the current Group Ownership scheme. As a result of the changes, the maximum total compensation for the Group Chief Executive is reducing by almost 30 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Flavor maker McCormick & Co., Inc. is recalling certain McCormick and Frank's brand seasoning products citing possible salmonella risk, the U.S. Food and Drug Administration said. The recall involves McCormick Perfect Pinch Italian Seasoning, McCormick Culinary Italian Seasoning and Frank's RedHot Buffalo Ranch Seasoning. Drug major Pfizer Inc. raised Wednesday its outlook for fiscal 2021 earnings and revenues following strong second quarter results that exceeded market estimates. According to the company, the upward revision in full-year outlook, for the second quarter in a row, reflects its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE COVID-19 vaccine. While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2021. For fiscal 2021, the company now projects earnings in a range of $3.18 to $3.38 per share,...
Follow RTT